Spectrum Pharmaceuticals ceased to exist as an independent publicly traded entity following its official acquisition by Assertio Holdings. Under the terms of the merger agreement, former Spectrum shareholders received a fixed fraction of Assertio common stock alongside contingent value rights tied to future commercial sales milestones of their primary drug asset, Rolvedon. Following the transaction completion, Spectrum's common stock was delisted from public exchanges.